AF1q Expression Associates with CD44 and STAT3 and Impairs Overall Survival in Adenoid Cystic Carcinoma of the Head and Neck.


Journal

Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 10 05 2019
accepted: 23 06 2019
pubmed: 6 7 2019
medline: 27 3 2021
entrez: 6 7 2019
Statut: ppublish

Résumé

Salivary gland malignancies of the head and neck form a heterogeneous group. Adenoid cystic carcinomas are an aggressive entity of salivary gland malignancies characterized by frequent distant metastases and poor response to radio- and chemotherapy. AF1Q is a MLL fusion partner, which can activate Wnt and STAT3 signaling. Recently, overexpression of AF1q has been identified as a poor prognosticator in patients of different malignancies. A total of 46 patients with adenoid cystic carcinoma were immunohistochemically evaluated for expression of AF1q and clinical outcome was analyzed in this context. Additionally, STAT3 and the Wnt downstream target CD44 were investigated and correlated with AF1q. AF1q was overexpressed in 52.2%. Overexpression of AF1q was associated with poorer overall survival (p = 0.03). Additionally, lymph node metastases and solid tumor parts were more frequently observed in AF1qhigh patients (p = 0.07 and 0.05, respectively). AF1q did not influence the occurrence of distant metastases. Expression of AF1q was associated with higher levels of STAT3 and CD44 (p = 0.003 and 0.006, respectively). AF1q is a novel prognostic marker for poor overall survival in adenoid cystic carcinoma patients. The deleterious effects on survival may be a result of promotion of the STAT3 and Wnt pathway.

Identifiants

pubmed: 31273546
doi: 10.1007/s12253-019-00696-z
pii: 10.1007/s12253-019-00696-z
pmc: PMC7242261
doi:

Substances chimiques

Biomarkers, Tumor 0
CD44 protein, human 0
Hyaluronan Receptors 0
MLLT11 protein, human 0
Neoplasm Proteins 0
Proto-Oncogene Proteins 0
STAT3 Transcription Factor 0
STAT3 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1287-1292

Références

Biomed Mater Eng. 2015;26 Suppl 1:S2145-53
pubmed: 26405993
PLoS One. 2012;7(6):e39968
pubmed: 22761939
Am J Clin Oncol. 2011 Feb;34(1):76-81
pubmed: 20177363
Am J Surg. 1974 Oct;128(4):512-20
pubmed: 4371368
Oncol Rep. 2010 Aug;24(2):547-54
pubmed: 20596645
Head Neck. 2017 Mar;39(3):456-463
pubmed: 27775851
Oncotarget. 2016 Jul 12;7(28):43960-43973
pubmed: 27259262
Oncotarget. 2017 Apr 4;8(14):23246-23264
pubmed: 28423573
Int J Mol Sci. 2017 May 05;18(5):
pubmed: 28475127
Cancer. 1984 Sep 15;54(6):1062-9
pubmed: 6088017
Am J Cancer Res. 2015 Apr 15;5(5):1751-61
pubmed: 26175943
Head Neck. 2015 Jan;37(1):30-6
pubmed: 24500803
Biochem Biophys Res Commun. 2017 Mar 18;484(4):884-889
pubmed: 28188793
J Laryngol Otol. 2016 May;130(S2):S142-S149
pubmed: 27841127
Eur Arch Otorhinolaryngol. 2016 May;273(5):1283-92
pubmed: 25801951
Blood. 1995 Feb 1;85(3):650-6
pubmed: 7833468
Arch Otolaryngol Head Neck Surg. 1999 Feb;125(2):149-52
pubmed: 10037280
Cancer. 1978 Jul;42(1):265-82
pubmed: 208752
Oncotarget. 2015 Aug 21;6(24):20697-710
pubmed: 26079538

Auteurs

Lorenz C Kadletz (LC)

Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, Vienna, Austria. lorenz.kadletz@meduniwien.ac.at.

Faris F Brkic (FF)

Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.

Bernhard J Jank (BJ)

Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.

Sven Schneider (S)

Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.

Julia Cede (J)

Department of Craniomaxillo and Facial Surgery, Medical University of Vienna, Vienna, Austria.

Rudolf Seemann (R)

Department of Craniomaxillo and Facial Surgery, Medical University of Vienna, Vienna, Austria.

Elisabeth S Gruber (ES)

Department of General Surgery, Division of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Elisabeth Gurnhofer (E)

Department of Experimental Pathology and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria.

Gregor Heiduschka (G)

Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.

Lukas Kenner (L)

Department of Experimental Pathology and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at.
Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria. lukas.kenner@meduniwien.ac.at.
Department of Experimental Pathology and Laboratory Animal Pathology, University of Veterinary Medicine, Vienna, Austria. lukas.kenner@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH